Latest News
Vermillion names James LaFrance as CEO
24 April 2014 - Diagnostics company Vermillion (NasdaqCM :VRML) revealed on Wednesday the appointment of James LaFrance as its president and chief executive officer.

The company added LaFrance will continue to serve as its board chairman and succeeds Thomas McLain in the new roles.

Most recently, LaFrance has served as CEO of Omnyx, a joint venture of GE and UPMC in Pittsburgh.

Previously, LaFrance was employed with Ventana Medical Systems in global marketing and business development, as well as domestic and international commercial general management. In the past, he has led global marketing and business development for the Near Patient Testing division of Bayer Diagnostics.

Login
Username:

Password: